Description

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Company News Around The Web

SNGX
Symbol
Exchange
Open
Day Low
Day High
Volume
Average Volume
Market Cap
Shares Outstanding
EPS (TTM)
P/E Ratio
Dividend Yield
- -
0.00%% 0.00
Ticker -
Exchange -
Open -
Day Low - High -
Volume
Average Volume
Year Low - High -
Market Cap -
Shares Outstanding -
EPS -
P/E -
Dividend/Yield -
Institutional Ownership -